潜在抗肺动脉高压新型靶向药物——伊马替尼  

A Potential Novel Targeted Drug for the Treatment of Pulmonary Arterial Hypertension:Imatinib

作　　者：谢珊珊[1] 李叶 余玲玲[3] 万瑾瑾 黄志英 林环玉 张卫芳[1] XIE Shanshan;LI Ye;YU Lingling;WAN Jinjin;HUANG Zhiying;LIN Huanyu;ZHANG Weifang(Department of Pharmacy,the Second Affiliated Hospital of Nanchang University,Nanchang 330006,China;Medical College of Nanchang University,Nanchang 330031,China;Department of Rehabilitation Medicine,the Second Affiliated Hospital of Nanchang University,Nanchang 330006,China)

机构地区：[1]南昌大学第二附属医院药学部,南昌330006 [2]南昌大学医学院,南昌330031 [3]南昌大学第二附属医院康复科,南昌330006

出　　处：《医药导报》2024年第2期262-266,共5页Herald of Medicine

基　　金：江西省教育厅重点项目(GJJ2200103)。

摘　　要：肺动脉高压死亡率高,目前虽然有靶向药物治疗,但仍无法治愈,患者长期预后不佳。伊马替尼作为一种酪氨酸激酶抑制剂,2002年在中国获批上市,用于治疗慢性粒细胞白血病等多种肿瘤疾病。研究发现伊马替尼除可抗肿瘤外,还可改善严重肺动脉高压患者的血流动力学和运动耐量,但安全性欠佳。随着伊马替尼靶向肺部新剂型的出现,该药有望成为抗肺动脉高压的新型靶向药物。Pulmonary hypertension has a high mortality rate,and although targeted therapy is available,it is still incurable,and the long-term prognosis for patients is poor.As a tyrosine kinase inhibitor,imatinib was approved for marketing in China in 2002 for the treatment of chronic myelogenous leukemia and other tumor diseases.In addition to the antitumor effects,imatinib was found to improve hemodynamics and exercise tolerance in patients with severe pulmonary arterial hypertension,but the safety was suboptimal.With the emergence of new formulations of imatinib targeted at the lungs,it is expected to become a new targeted drug for pulmonary arterial hypertension.

关 键 词：伊马替尼 肺动脉高压 新型制剂 

分 类 号：R972.4[医药卫生—药品] R563.9[医药卫生—药学]